Published in PLoS One on March 10, 2014
Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome. PLoS One (2016) 0.81
Urinary nerve growth factor could be a biomarker for interstitial cystitis/painful bladder syndrome: a meta-analysis. PLoS One (2014) 0.78
Effects of CYP-Induced Cystitis on Growth Factors and Associated Receptor Expression in Micturition Pathways in Mice with Chronic Overexpression of NGF in Urothelium. J Mol Neurosci (2016) 0.75
Elevated level of nerve growth factor in the bladder pain syndrome/interstitial cystitis: a meta-analysis. Springerplus (2016) 0.75
Urodynamic prognostic factors for large post-void residual urine volume after intravesical injection of onabotulinumtoxinA for overactive bladder. Sci Rep (2017) 0.75
From bladder to systemic syndrome: concept and treatment evolution of interstitial cystitis. Int J Womens Health (2015) 0.75
Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp Neurol (2000) 2.01
Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol (2010) 1.96
The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritis. Urology (2007) 1.79
Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitis. J Urol (2012) 1.75
Do cystometric findings predict the results of intravesical hyaluronic acid in women with interstitial cystitis? Eur Urol (2004) 1.54
Mechanisms of Disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol (2006) 1.46
Effect of hyaluronic acid on urine nerve growth factor in cyclophosphamide-induced cystitis. Int J Urol (2011) 1.42
Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome. Int J Urol (2009) 1.40
Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J Urol (1991) 1.32
Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int (2009) 1.28
Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology (2005) 1.27
Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. Neurourol Urodyn (2011) 1.25
BDNF: a neuromodulator in nociceptive pathways? Brain Res Brain Res Rev (2002) 1.21
Interstitial cystitis: a chronic pelvic pain syndrome. Med Clin North Am (2004) 1.18
A deficit of chondroitin sulfate proteoglycans on the bladder uroepithelium in interstitial cystitis. Urology (1996) 1.13
Functional and structural characteristics of the glycosaminoglycans of the bladder luminal surface. J Urol (1987) 1.12
Treatment of interstitial cystitis with Cystistat: a hyaluronic acid product. Scand J Urol Nephrol (2005) 1.04
Increased urine and serum nerve growth factor levels in interstitial cystitis suggest chronic inflammation is involved in the pathogenesis of disease. PLoS One (2012) 1.03
Hyaluronic acid: an effective alternative treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis? Eur Urol (2007) 1.01
Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol (1996) 1.01
Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis. Int Urogynecol J (2010) 0.98
Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct (2007) 0.95
Urinary neurotrophic factors in healthy individuals and patients with overactive bladder. J Urol (2012) 0.93
Sequestration of brain derived nerve factor by intravenous delivery of TrkB-Ig2 reduces bladder overactivity and noxious input in animals with chronic cystitis. Neuroscience (2010) 0.90
Neurotrophins as regulators of urinary bladder function. Nat Rev Urol (2012) 0.90
Results of treatment of refractory interstitial cystitis with intravesical hyaluronic acid. Urol Int (1997) 0.89
Uronate peaks and urinary hyaluronic acid levels correlate with interstitial cystitis severity. J Urol (2006) 0.89
Intravesical onabotulinumtoxinA injections for refractory painful bladder syndrome. Pain Physician (2012) 0.87
Intravesical hyaluronic acid for interstitial cystitis/painful bladder syndrome: a comparative randomized assessment of different regimens. Int J Urol (2012) 0.85
Effect of intravesical glycosaminoglycan substitution therapy on bladder pain syndrome/interstitial cystitis, bladder capacity and potassium sensitivity. Scand J Urol Nephrol (2008) 0.82
Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study. Eur Urol (2014) 2.86
Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis. Int J Urol (2014) 2.17
Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study. Neurourol Urodyn (2015) 0.94
Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn (2014) 0.84
Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of Disease. Int Neurourol J (2016) 0.83
Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center. Neurourol Urodyn (2015) 0.81
Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome. Int Neurourol J (2015) 0.81
Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome. PLoS One (2016) 0.81
Urothelial dysfunction and chronic inflammation in patients with spinal cord injuries at different levels and correlation with urodynamic findings. Neurourol Urodyn (2014) 0.79
Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder. PLoS One (2014) 0.79
Long-term follow up and predictive factors for successful outcome of transurethral incision of the bladder neck in women with detrusor underactivity. J Formos Med Assoc (2015) 0.78
Revisiting the Role of Potassium Sensitivity Testing and Cystoscopic Hydrodistention for the Diagnosis of Interstitial Cystitis. PLoS One (2016) 0.77
Potential Biomarkers Utilized to Define and Manage Overactive Bladder Syndrome. Low Urin Tract Symptoms (2012) 0.77
Urothelial dysfunction and increased suburothelial inflammation of urinary bladder are involved in patients with upper urinary tract urolithiasis--clinical and immunohistochemistry study. PLoS One (2014) 0.77
Long-term Combination Therapy With α-Blockers and 5α-Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From Medication. Int Neurourol J (2016) 0.75
Urodynamic prognostic factors for large post-void residual urine volume after intravesical injection of onabotulinumtoxinA for overactive bladder. Sci Rep (2017) 0.75
Video-urodynamic characteristics of non-neurogenic, idiopathic underactive bladder in men - A comparison of men with normal tracing and bladder outlet obstruction. PLoS One (2017) 0.75
OnabotulinumtoxinA Urethral Sphincter Injection as Treatment for Non-neurogenic Voiding Dysfunction - A Randomized, Double-Blind, Placebo-Controlled Study. Sci Rep (2016) 0.75
The Role of Immunoglobulin E in the Pathogenesis of Ketamine Related Cystitis and Ulcerative Interstitial Cystitis: An Immunohistochemical Study. Pain Physician (2016) 0.75
Recent research on the role of urodynamic study in the diagnosis and treatment of male lower urinary tract symptoms and urinary incontinence. Ci Ji Yi Xue Za Zhi (2017) 0.75
ICS teaching module: Artefacts in urodynamic pressure traces (basic module). Neurourol Urodyn (2015) 0.75
Botulinun A toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction. Ci Ji Yi Xue Za Zhi (2016) 0.75
Recent advances in recurrent urinary tract infection from pathogenesis and biomarkers to prevention. Ci Ji Yi Xue Za Zhi (2017) 0.75
Current consensus and controversy on the treatment of male lower urinary tract symptoms/benign prostatic hyperplasia. Ci Ji Yi Xue Za Zhi (2017) 0.75
Pathophysiology of benign prostate enlargement and lower urinary tract symptoms: Current concepts. Ci Ji Yi Xue Za Zhi (2017) 0.75
Videourodynamic factors predictive of successful onabotulinumtoxinA urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity. Low Urin Tract Symptoms (2017) 0.75
Current consensus and controversy on the diagnosis of male lower urinary tract symptoms/benign prostatic hyperplasia. Ci Ji Yi Xue Za Zhi (2017) 0.75
Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder. Neurourol Urodyn (2015) 0.75
Patient characteristics for different therapeutic strategies in the management ketamine cystitis. Neurourol Urodyn (2016) 0.75
Videourodynamic analysis of the urethral sphincter overactivity and the poor relaxing pelvic floor muscles in women with voiding dysfunction. Neurourol Urodyn (2017) 0.75